Please choose a legal issue for more:

---

PharmStar Pharmaceuticals Reaches Agreement to Purchase 24,000 Sq. Ft. Manufacturing Facility

PharmStar Pharmaceuticals, Inc. ( PINKSHEETS : PHAR ), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever AQUAPRIN™, announced today that it has reached an agreement in principle to purchase ...

Vertex Pharmaceuticals Inc. Spiked To A New 52-Week High

(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX: News ) spiked sharply to the upside around mid-morning Tuesday, but settled into a range for the remainder of the day. The surge in stock price coincided with the release of an FDA review of telaprevir, Vertex ...

Watson Pharmaceuticals Q1 Profit Drops - Quick Facts

(RTTNews) - Watson Pharmaceuticals, Inc. (WPI: News ) reported net income attributable to common shareholders of $45.3 million or $0.36 per share for the first quarter, lower than $69.8 million or $0.57 per share reported a year earlier. On a non-GAAP ...

Jazz Pharmaceuticals (JAZZ) Short Sale Rule In Effect

Get Access to this story and many, many, more. You can choose to sign up for a Premium Subscription, Free Basic Subscription, or a Free 2-Week Premium Trial! With StreetInsider Premium, you will have access to fully-categorized, up-to-the-minute news ...

BioSante Pharmaceuticals, Inc. To Present at the Deutsche Bank Annual Health Care Conference

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Apr 27, 2011 - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the 36 th Annual Deutsche Bank Health Care Conference to be held at the InterContinental Hotel, Boston from May 2-4, 2011. Phillip B ...

Regeneron Pharmaceuticals, Sanofi-Aventis' Zaltrap Meets Goals

NEW YORK -- Regeneron Pharmaceuticals Inc. and partner Sanofi-Aventis' potential cancer drug met key goals in a late-stage study focusing on colon cancer patients. Late Tuesday, the companies said that Zaltrap, in combination with chemotherapy, met the key ...

Aegerion Pharmaceuticals Appoints Mark J. Fitzpatrick as Chief Financial Officer

CAMBRIDGE, Mass., April 27, 2011 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR - News ), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders ...

Equity Research on Valeant Pharmaceuticals International and Hospira Inc. - Demand, Approval and Takeovers Dominate Drug Delivery

JOHANNESBURG, SOUTH AFRICA--(Marketwire - 04/27/11) - www.stockcall.com/ offers investors comprehensive research on the Drug Delivery industry and has completed analytical research on Valeant Pharmaceuticals International (NYSE: VRX - News ) and Hospira ...

Cadence Pharmaceuticals' CEO Ted Schroeder to Present at Three Investment Conferences During the Mon

Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that the company's President and CEO ...

Spectrum Pharmaceuticals Announces Record Revenue and Record Profit in First Quarter 2011

IRVINE, Calif.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI - News ), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced preliminary unaudited first ...

New Market Study Published: Switzerland Pharmaceuticals & Healthcare Report Q2 2011

PRLog (Press Release) – Apr 20, 2011 – BMI View: Despite the threat of austerity measures, the Swiss government's focus on cost-containment within the pharmaceuticals and healthcare sector and the impact of generic competition as a result of the patent ...

Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference

MALVERN, Pa. , April 20, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL - News ) today announced that executive management will participate in the Deutsche Bank 36th Annual Health Care Conference during May 2-4, 2011 at the ...

Ampio Pharmaceuticals closes final placement of shares

Apr 20, 2011 (M2 EQUITYBITES via COMTEX) -- Drug development company Ampio Pharmaceuticals Inc on Tuesday announced the successful completion of a private placement from which Ampio received gross proceeds of USD12.732m. Under the private placement, Ampio ...

Murphy Analytics Initiates Research Coverage on Tibet Pharmaceuticals

Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China , today announced the release of an in-depth initiation report by ...

Cumberland Pharmaceuticals Acquires Rights to Ifetroban Molecule

April 20--Cumberland Pharmaceuticals Inc. said Tuesday that it has agreed to acquire rights to a molecule named ifetroban that it plans to test as a potential in-hospital treatment for a condition that involves progressive kidney failure. The purchase adds ...

TRACON Pharmaceuticals Raises $14M

San Diego-based TRACON Pharmaceuticals , a firm developing cancer therapeutics, said this morning that it has raised $14M in a first tranche closing of a venture round. The round was led by JAFCO and Nextech Invest, and also included Arcus Ventures, BHP ...

ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2011 Financial Results

Conference call access: Internet: www.istavision.com Domestic dial-in: 866-761-0749 International dial-in: 617-614-2707 Passcode: 51591817 To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants ...

The Ludwig Institute and Pro-Pharmaceuticals Discover That DAVANAT Enhances the Ability of Anti-Tumor T Lymphocytes to Kill Tumor Cells

Pro-Pharmaceuticals' DAVANAT ® Targets Galectin Proteins Secreted by Cancer Cells and Eliminates The Cancer's Ability to Evade the Immune System NEWTON, Mass.--(BUSINESS WIRE)--Apr 20, 2011 - Pro-Pharmaceuticals, Inc. (OTC:PRWP) today announced that the ...

Ligand Partner Prism Pharmaceuticals to be Acquired by Baxter

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND ) announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc. (NYSE: BAX ). Prism Pharmaceuticals ...

Valeant Pharmaceuticals Announces Redemption of 4.0% Convertible Subordinated Notes Due 2013

MISSISSAUGA, Ontario , April 20, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX - News ) today announced that it will redeem all of the outstanding 4.0% Convertible Subordinated Notes due 2013 (the "Notes") of its wholly-owned ...

---

Pages:   1   2   3   4   5   6   ...   Next